Giredestrant plus Everolimus in Advanced Breast Cancer.
Erica L Mayer, Sara M Tolaney, Miguel Martín et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase 3 randomized controlled trial evaluated the efficacy of giredestrant plus everolimus versus standard endocrine therapy plus everolimus in patients with ER-positive, HER2-negative advanced breast cancer who had progressed after CDK4/6 inhibitor treatment. Among patients with ESR1-mutated tumors, median progression-free survival was 10.0 months for the giredestrant-everolimus group compared to 5.5 months for standard therapy-everolimus (hazard ratio 0.38, P<0.001).
Key findings
- In patients with ESR1-mutated tumors, median progression-free survival was 10.0 months with giredestrant-everolimus versus 5.5 months with standard therapy-everolimus.
- In the overall population, median progression-free survival was 8.8 months for giredestrant-everolimus compared to 5.5 months for standard therapy-everolimus.
- Adverse events occurred in 98.9% of patients receiving giredestrant-everolimus and 96.8% of those receiving standard therapy-everolimus.
Why it matters
The findings suggest that the giredestrant-everolimus combination may offer a more effective treatment option for patients with advanced breast cancer who have developed resistance to prior therapies, particularly in those with ESR1 mutations.